The Jackson Park Capital LLC Acquires New Stake in Nabriva Therapeutics AG (NBRV)

The Jackson Park Capital LLC Acquires New Stake in Nabriva Therapeutics AG (NBRV)

Jackson Park Capital LLC acquired a new position in Nabriva Therapeutics AG (NASDAQ:NBRV) during the second quarter, Holdings Channel reports. The firm acquired 26,000 shares of the company’s stock, valued at approximately $195,000.

Separately, Vivo Capital LLC acquired a new position in Nabriva Therapeutics AG during the first quarter worth approximately $28,239,000. Institutional investors and hedge funds own 63.05% of the company’s stock.

Nabriva Therapeutics AG (NASDAQ:NBRV) traded down 0.70% during midday trading on Friday, reaching $7.11. The company’s stock had a trading volume of 7,507 shares. The firm’s market cap is $151.14 million. The firm has a 50 day moving average price of $7.51 and a 200-day moving average price of $7.93. Nabriva Therapeutics AG has a 52 week low of $6.61 and a 52 week high of $10.69.

Nabriva Therapeutics AG (NASDAQ:NBRV) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.50) EPS for the quarter, topping the Zacks’ consensus estimate of ($6.25) by $5.75. On average, analysts forecast that Nabriva Therapeutics AG will post ($1.93) earnings per share for the current fiscal year.

Several brokerages recently issued reports on NBRV. Zacks Investment Research lowered Nabriva Therapeutics AG from a “buy” rating to a “hold” rating in a research note on Wednesday, June 29th. Wedbush restated an “outperform” rating and set a $17.00 price target on shares of Nabriva Therapeutics AG in a research note on Tuesday, August 9th. Finally, HC Wainwright began coverage on Nabriva Therapeutics AG in a research note on Thursday, September 8th. They set a “buy” rating and a $16.00 price target on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Nabriva Therapeutics AG presently has an average rating of “Buy” and a consensus target price of $15.89.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).

Related posts

Leave a Comment